Status:
COMPLETED
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
Lead Sponsor:
Frank A. Bucci, Jr., M.D.
Collaborating Sponsors:
Allergan
Conditions:
Cataracts
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instru...
Eligibility Criteria
Inclusion
- Subjects must be 18 years of age or older.
- Scheduled for cataract surgery by phacoemulsification.
- Subject must be willing to comply with all study requirements and be willing to give informed consent.
Exclusion
- Any subject that has a history of uveitis or active iritis.
- Subject can have no previous eye surgery, with the exception of refractive surgery, but not within 6 months.
- No ocular use of prostaglandins within 2 weeks of surgery.
- Use of oral, injectable or topical ophthalmic steroids, nonsteroidal anti-inflammatory (NSAIDS) or immunosuppressants within 14 days prior to surgery.
- Contraindications to NSAIDS.
- Active ocular infection.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT01001806
Start Date
October 1 2009
End Date
January 1 2010
Last Update
October 3 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bucci Laser Vision Institute
Wilkes-Barre, Pennsylvania, United States, 18702